ArticleScientific reports2025
Biological activity, UHPLC-MS phytochemical profiling, and computational studies of the leaf extract of Acridocarpus socotranus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soqotra Island is renowned for its exceptional biodiversity, harboring approximately 825 plant species, 307 of which (37%) are endemic. Despite its rich traditional knowledge, many of these plants remain scientifically underexplored. This study, for the first time, investigates the phytochemical composition, biological activities, and molecular interactions of Acridocarpus socotranus, an endemic species traditionally used to treat rheumatism and skin disorders. A comprehensive UHPLC-MS analysis of the methanol leaf extract identified 25 phytochemicals, classified into seven major categories: alkaloids, terpenoids, flavonoids, coumarins, glycosides, steroids, and other organic compounds. The extract exhibited a high phenolic content (95.6 ± 4.90 mg GAE/g). Enzyme inhibition assays revealed that the extract effectively suppressed the activity of several enzymes, including mushroom monophenolase (IC₅₀: 125 µg/mL), diphenolase (IC₅₀: 191.07 µg/mL), xanthine oxidase (IC₅₀: 127.8 µg/mL), and glyoxalase I (IC₅₀: 0.27 µg/mL). Cytotoxicity testing showed that the extract was very effective at stopping the growth of colorectal cancer (SW480 and HCT116) cells (IC₅₀: 259.7 ± 12.1 and 146.3 ± 10.9 µg/mL, respectively), but it was less effective against breast cancer (MCF7 and MDA-MB-231) and prostate (PC3) cell lines (IC₅₀ > 350 µg/mL). . Molecular docking further confirmed these findings, revealing that phytochemicals from A. socotranus can effectively bind to glyoxalase I and to a conserved pocket of the salivary protein tablysin-15. The observed binding patterns resemble those of known antagonists that neutralize inflammatory mediators rather than blocking their receptors. These antagonist-like interactions suggest a potential anti-inflammatory mechanism, thereby providing additional therapeutic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.